🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Verastem clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our USA, UK and Ireland registers with Verastem as lead sponsor. Synced 26 Sep 2026
8Current trials
5Recruiting now
16Drugs in these trials
3Trial registers
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Verastem is the lead sponsor of 8 current clinical trials in our USA, UK and Ireland registers. 5 are recruiting patients now. The most common phase is Phase 2. The drugs named most often in its trials are VS-7375, Cetuximab and Avutometinib. The most-studied condition is Non Small Cell Lung Cancer.

ClinicalTrials.gov trials by status

  • Recruiting563%
  • Active, closed338%

Trials by phase

  • Phase 2450%
  • Phase 1/2338%
  • Phase 3113%
01

Clinical trials sponsored by Verastem

8 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
NCT06072781 · Low Grade Serous Ovarian Cancer
Phase 3 Recruiting 2024-03 Ireland, UK, USA
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
NCT07659782 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer
Drug: VS-7375
Phase 2 Recruiting 2026-07 USA
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
NCT07644559 · ClinicalTrials.gov ↗ · Pancreatic Ductal Adenocarcinoma (PDAC), G12D Mutated KRAS
Phase 2 Recruiting 2026-06 USA
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
NCT07020221 · ClinicalTrials.gov ↗ · Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer, Colorectal Cancer
Phase 1/2 Recruiting 2025-06 USA
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer
NCT07659795 · ClinicalTrials.gov ↗ · Colorectal Cancer
Phase 2 Recruiting 2026-07 USA
Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients
NCT05074810 · Non Small Cell Lung Cancer, KRAS Activating Mutation
Phase 1/2 Active, closed 2022-04 UK, USA
Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer
NCT05669482 · KRAS Activating Mutation, Metastatic Cancer, Pancreas Cancer
Phase 1/2 Active, closed 2023-03 USA
A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation
NCT04625270 · ClinicalTrials.gov ↗ · Low Grade Ovarian Serous Adenocarcinoma, Ovarian Cancer
Phase 2 Active, closed 2020-12 UK, USA

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Verastem trials

16 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Verastem trials

14 conditions
04

By trial register

RegisterTrialsRecruiting
Clinical trials in USA85
Clinical trials in UK31
Clinical trials in Ireland11

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Non Small Cell Lung Cancer

SponsorTrials
Hunan Province Tumor Hospital10
MediLink Therapeutics (Suzhou)4
Shanghai Henlius Biotech4
Peking Union Medical College Hospital4
Nuvation Bio3
Guangdong Association of Clinical Trials3
OncoC42
HUYABIO International2
N-Power Medicine2
Tango Therapeutics2

Sponsors with the most current trials registered for this condition.

06

Questions about Verastem trials

How many clinical trials does Verastem sponsor?

Verastem is the lead sponsor of 8 current trials on ClinicalTrials.gov in our USA, UK and Ireland registers, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Verastem trials recruiting?

Yes. 5 of its 8 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Verastem testing?

Its current trials name 16 drugs and biologicals as interventions. The most frequent are VS-7375 (4), Cetuximab (3), Avutometinib (2), Avutometinib (VS-6766) and defactinib (2) and Anastrozole (1). The number in brackets is how many of its trials name each drug.

Does Verastem have clinical trials in Ireland?

Yes. 1 trial in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.